You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,206,711

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,206,711

Title:	Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies
Abstract:	Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
Inventor(s):	White; Christine A. (Rancho Santa Fe, CA), Grillo-Lopez; Antonio J. (Rancho Santa Fe, CA), Curd; John G. (Hillsborough, CA), Desmond-Hellmann; Susan (Alamo, CA)
Assignee:	Biogen Idec Inc. (Cambridge, MA) Genentech, Inc. (South San Francisco, CA)
Application Number:	12/629,472
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,206,711
Patent Claims:	1. A method of treating chronic lymphocytic leukemia (CLL) in a human patient, comprising administering rituximab to the patient in an amount effective to treat the CLL, wherein the rituximab is administered to the patient at a dosage of 500 mg/m.sup.2. 2. The method of claim 1 further comprising administering a chemotherapeutic regimen to the patient. 3. The method of claim 2 wherein the chemotherapeutic regimen comprises fludarabine. 4. The method of claim 2 wherein the chemotherapeutic regimen comprises cyclosphosphamide. 5. The method of claim 1 wherein the rituximab is administered weekly. 6. The method of claim 1 wherein the rituximab is administered bi-weekly. 7. The method of claim 1 wherein the rituximab is administered monthly. 8. The method of claim 1 which does not include treatment with a radiolabeled anti-CD20 antibody. 9. A method of treating chronic lymphocytic leukemia (CLL) in a human patient, comprising administering rituximab to the patient in an amount effective to treat the CLL, wherein the rituximab is administered to the patient at dosages of 500 mg/m.sup.2, and further comprising administering a chemotherapeutic regimen to the patient, wherein the chemotherapeutic regimen comprises fludarabine and cyclophosphamide.

Details for Patent 8,206,711

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2018-11-09
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2018-11-09
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2018-11-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.